Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising plans through debt or equity in the provided transcript. The management did not discuss raising capital or issuing shares during the call. Rajesh Aggarwal confirmed no promoter share offloading or reduction has occurred; in fact, promoter holding increased due to past buyback. The focus is on internal growth through new product launches, R&D, backward integration, and improving profitability rather than external fundraising. No specific financial plans involving raising capital were shared for the near future.

Any current/future capex/capital investment/strategic investment?

Completed project at Chopanki; plant is up and functioning with full-fledged technical production. New molecules from Chopanki unit have already been launched in the market. Announced a new plant at Sotanala (Behror); company in final stages of acquisition with registry expected in early June. Plans to start production of formulations and biologicals from the new site, with technicals production as Phase 2 in a phased approach. Focus on backward integration initiatives supporting business momentum and growth.

Future growth expectations in sales/revenue/volumes?

Targeting double-digit revenue growth of 10% to 12% in fiscal year 2024. Expecting significant growth in exports, aiming to double export sales compared to the previous year. Planning gross sales of over INR 800 crores in Q1, supported by new product launches and higher sales targets. New patented and branded products (e.g., Shinwa, Hachiman, Torry, Mission) expected to contribute substantially, with Focused Maharatna and Maharatna segments projected to account for at least 60% of sales in FY '24. Inventory liquidation and market normalization anticipated to improve margins and profita

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '24 expected to be challenging due to inventory liquidation and market pressures, but growth is anticipated. Revenue growth target for FY '24 is double-digit, around 10%-12%. EBITDA margin guidance for FY '24 is subdued at 9%-10%, with improvement expected post Q1 as lower cost inventories come into effect. The company aims to increase profitability beyond current 10% EBITDA margin to 12%+ in FY '25 when market normalizes and new, higher-margin patented products gain traction. New product launches, including patented products, expected to drive better margins and growth over the nex

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention a specific current or expected order book or pending orders value. Rajesh Aggarwal mentions strong sales targets, notably planning gross sales of INR 800 crores-plus in the first quarter, indicating a strong order pipeline. Demand for products remains good domestically, with no significant stocks in the market, suggesting steady off-take. Chinese inventory is still flowing into the market, which affects pricing but also indicates ongoing procurement and orders. The company is optimistic about growth from Q2 onwards, assuming normalization post monsoon

Insecticides India LtdQ4 FY23Fertilizers & Agrochemicals

Insecticides India Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹512.45P/E: 11.9Market Cap: ₹1.5K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Targeting double-digit revenue growth of 10% to 12% in fiscal year 2024.
Expecting significant growth in exports, aiming to double export sales compared to the previous year.
Planning gross sales of over INR 800 crores in Q1, supported by new product launches and higher sales targets.
New patented and branded products (e.g., Shinwa, Hachiman, Torry, Mission) expected to contribute substantially, with Focused Maharatna and Maharatna segments projected to account for at least 60% of sales in FY '24.
Inventory liquidation and market normalization anticipated to improve margins and profitability.
Anticipate recovery and growth as agricultural season picks up, with positive impact expected from monsoon timing and market conditions.
Expansion of product portfolio and R&D initiatives aimed at sustaining growth and entering new markets continuously.

Margin guidance

Category 2

FY '24 expected to be challenging due to inventory liquidation and market pressures, but growth is anticipated.
Revenue growth target for FY '24 is double-digit, around 10%-12%.
EBITDA margin guidance for FY '24 is subdued at 9%-10%, with improvement expected post Q1 as lower cost inventories come into effect.
The company aims to increase profitability beyond current 10% EBITDA margin to 12%+ in FY '25 when market normalizes and new, higher-margin patented products gain traction.
New product launches, including patented products, expected to drive better margins and growth over the next few years.
Export growth projected to double in FY '24, potentially boosting earnings.
Performance is expected to improve from Q2 FY '24 onwards, assuming favorable monsoon and easing of Chinese pricing pressures.
Long-term growth supported by R&D, backward integration, introduction of mega brands, and new markets expansion.

See what Insecticides India Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising plans through debt or equity in the provided transcript.
The management did not discuss raising capital or issuing shares during the call.
Rajesh Aggarwal confirmed no promoter share offloading or reduction has occurred; in fact, promoter holding increased due to past buyback.
The focus is on internal growth through new product launches, R&D, backward integration, and improving profitability rather than external fundraising.
No specific financial plans involving raising capital were shared for the near future.

Order book

The transcript does not explicitly mention a specific current or expected order book or pending orders value.
Rajesh Aggarwal mentions strong sales targets, notably planning gross sales of INR 800 crores-plus in the first quarter, indicating a strong order pipeline.
Demand for products remains good domestically, with no significant stocks in the market, suggesting steady off-take.
Chinese inventory is still flowing into the market, which affects pricing but also indicates ongoing procurement and orders.
The company is optimistic about growth from Q2 onwards, assuming normalization post monsoon.
While exact order book figures aren’t disclosed, the focus on inventory liquidation and ambitious Q1 sales targets implies a healthy pending order scenario.

See what Insecticides India Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Completed project at Chopanki; plant is up and functioning with full-fledged technical production.
New molecules from Chopanki unit have already been launched in the market.
Announced a new plant at Sotanala (Behror); company in final stages of acquisition with registry expected in early June.
Plans to start production of formulations and biologicals from the new site, with technicals production as Phase 2 in a phased approach.
Focus on backward integration initiatives supporting business momentum and growth.

Track Insecticides India Ltd — get its next earnings analysis in your feed

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisInsecticides India Ltd

Rev 3Mar 2

See where Insecticides India Ltd sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Insecticides India Ltd rank in Fertilizers & Agrochemicals?

Compare Insecticides India Ltd against every Fertilizers & Agrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Insecticides India Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear
Astec Lifescienc (Q2 FY27)
2.3% YoY decline. Key results statement takeaways from Astec Lifescienc's Q2 FY27 results statement — and how it ranks against sector peers.

Compare:vs Coromandel Inter vs UPL Ltd vs F A C T

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →